Researchers concluded that the ability to achieve pCR correlated to improved recurrence-free survival in melanoma.
Researchers from the FDA analyzed 10 RCTs conducted in patients with unresectable or metastatic melanoma who were treated with 1 of 3 drug types.
The combination of ipilimumab and nivolumab resulted in a higher rate of objective remissions compared with ipilimumab alone.
Adjuvant ipilimumab may improve overall survival in patients with resected high-risk melanoma.
Secondary end points were not significantly different between the 2 groups, including overall survival.